Objective. We assess the safety of performing the epidural placement or revision of spinal cord stimulation (SCS) in patients whose anticoagulation has been held (termed "anticoagulant-suspended" patients) in accordance with the 2017 Neurostimulation Appropriateness Consensus Committee (NACC) guidelines.
Subjects. Patients undergoing SCS were included in this institutional review board-approved study.
Design. A retrospective analysis of a prospectively collected database was performed. Any adverse event occurring within 90 days after SCS lead placement/revision was included.
Results. A total of 225 patients who had a total of 239 surgeries including lead placement or lead revision were included; 182 patients were not on anticoagulants, 37 patients used one anticoagulant, and six patients used two or more anticoagulants. There were 13 adverse events. Anticoagulant use as a whole had no significant relationship to operative or postoperative adverse effects (v 2 (1) 5 1.613, P > 0.05). No anticoagulant on its own contributed significantly to adverse events; however, a small set of surgical cases showed a significantly greater incidence of adverse events for patients on enoxaparin used in combination with other anticoagulants (P < 0.05, N 5 4).
Conclusions. This study is the first to demonstrate that anticoagulant-suspended patients have no increased risk of perioperative hemorrhagic or thromboembolic adverse effects following SCS surgery compared with nonanticoagulated patients. The findings of this study validate the safety of neuromodulation in anticoagulation-suspended patients, concurring with the findings of previously described case studies, which anecdotally described neuromodulation outcomes in patients whose anticoagulation regimen had been temporarily held.
Introduction
Anticoagulation therapy is a commonly used treatment regimen, indicated for prevention of thromboembolic events in a wide range of disease processes including atrial fibrillation, deep vein thrombosis, coronary artery disease, and hypercoagulable states. More than 6 million patients in the United States receive anticoagulation therapy [1] , and this widespread use of anticoagulants represents an important clinical concern for surgical candidates. While the safety and adverse effects of anticoagulant administration in surgery have been welldocumented in the literature, recommendations on the use of anticoagulants in surgical procedures vary significantly by the specific surgical procedure [2] . Each physician must balance the risk of hemorrhage in anticoagulated patients with the risk of thromboembolism following discontinuation of the anticoagulant [2, 3] . Bleeding and thromboembolism in neuromodulation procedures are especially critical due to the susceptibility of nervous system tissue to mass effect and ischemia.
Recently, the Neurostimulation Appropriateness Consensus Committee (NACC) published a series of guidelines regarding the management and prevention of hemorrhagic and thromboembolic adverse effects in patients undergoing implantation of neurostimulation devices. These recommendations detail appropriate use of specific anticoagulants in the perioperative period of neuromodulation surgery [4] . Further, these guidelines stratify bleeding risk according to the specific type of procedure, classifying some as high risk (paddle spinal cord stimulation [SCS] , deep brain stimulation), some as medium risk (percutaneous SCS), and others as low to intermediate risk (peripheral nerve stimulation) [4] .
SCS is an established, effective method of treating chronic pain, widely used in a diverse range of indications including failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), neuropathy, and radiculopathy [5] [6] [7] . Epidural hemorrhage and pocket hematoma are the two SCS-associated hemorrhagic adverse effects most commonly reported in the literature, although both are exceedingly rare: the incidence of epidural hematoma is reported to be 0.14-0.3% [8] [9] [10] . Epidural hematoma is a consequence of distortion and injury to the epidural venous plexus within the epidural space secondary to lead insertion, resulting in rupture and hemorrhage [11, 12] . The use of paddle SCS leads has been suggested to have a higher incidence of epidural hemorrhage than percutaneous SCS leads [4] .
For SCS placement, anticoagulation regimen must be temporarily held in the perioperative period in accordance with NACC guidelines to avoid hemorrhagic adverse effects, referred to as "anticoagulant suspension." Thus, the safety of performing neuromodulation procedures on anticoagulant-suspended patients must be addressed. Here, we demonstrate the safety of neuromodulation surgery in anticoagulant-suspended patients in accordance with NACC guidelines.
Methods

Participants
Procedures followed were in accordance with the ethical standards of the institutional review board of the authors' institution. Patients undergoing SCS as part of their standard of care were included in this study. A retrospective analysis of a prospectively collected database was performed. Enrolled patients must have been competent to provide informed consent and fluent in English to have participated in this study. Any patient with a significant underlying psychiatric condition that would interfere with study protocol requirements was excluded from this study. All surgeries were performed by two experienced functional neurosurgeons at the authors' institution.
Data Collection
Diagnosis, gender, age, and anticoagulation regimen at the time of surgery were noted for each patient. Surgeries included in analysis consisted of initial SCS surgeries and revisions that included epidural surgery. All adverse effects that occurred within 90 days following the date of surgery were recorded. Eligible thromboembolic adverse events included, but were not limited to, hematoma, gastrointestinal bleed, myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, and mesenteric ischemia.
Data Analysis
The effect of anticoagulant use on risk of adverse effects was evaluated in this study. Each analysis was conducted over the total number of surgeries undergone by the patient population. We had one patient who underwent separate placement of the thoracic and cervical systems, which were considered two surgeries. Revisions on patients in the primary surgery cohort were also considered two surgeries. The patient population was first divided into groups based on anticoagulant use at time of surgery (no anticoagulant use, one anticoagulant used, two or more anticoagulants used in combination). Chi-square analysis was used to determine the relationship of anticoagulant use to incidence of adverse effects. The groups were further divided into use of specific anticoagulants; these included aspirin alone, apixaban (Eliquis) alone, enoxaparin (Lovenox) alone, enoxaparin in combination with other anticoagulants, and all other combinations of anticoagulants. The use of each anticoagulant was analyzed for a relationship with adverse effects by a Fisher exact test. All analyses were completed using IBM SPSS version 24 (IBM, Armonk, NY, USA) for Windows. Significance was determined at P < 0.05.
Results
Demographics
Patient demographics are provided in Table 1 . A total of 225 consecutive patients undergoing 239 surgeries were included in the study. This included 226 initial lead placements (one patient had cervical and thoracic leads placed simultaneously) and 14 lead-related revisions within 90 days of placement. There were 137 (61%) females and 88 (39%) males, with a mean age of 55 6 0.78 years (mean 6 SEM). Twenty-seven (12%) patients underwent cervical SCS implants while 196 (87%) underwent thoracic SCS implants. Two patients received both cervical and thoracic implants. Seventythree percent of the patients were implanted with paddles, 26% with percutaneous leads, and 1% with one of each.
Forty-three patients (19%) were using an anticoagulant, with 37 patients on one medication and six patients on two medications. Of note, three of these patients were bridged on and off warfarin with enoxaparin. Thus, they were not truly on two anticoagulants at baseline; however, for the purpose of this study and as the adverse effect was not clearly only related to enoxaparin, we characterized this as "on two anticoagulants." The majority of patients were taking aspirin due to a history of hyperlipidemia or family history of coronary artery disease (CAD; N ¼ 24) at the recommendation of their primary care physician. Others were using aspirin for pain relief (N ¼ Of the 46 surgeries on patients suspended from anticoagulants, four adverse events occurred, two of which were hematomas. Chi-square analysis determined no significant effect of anticoagulants on SCS adverse effects (v 2 (1) ¼ 1.613, P > 0.05). Two events occurred in the 39 cases on one anticoagulant, and two events occurred in the seven cases on two or more anticoagulants. The latter two occurred in patients being bridged on/off enoxaparin with warfarin, and the adverse events associated with both cases were hemorrhagic (intracranial hemorrhage and hematoma). There was no significant difference in adverse events when one or more than one anticoagulant was used (v 2 (1) ¼ 1.686, P > 0.05). However, when comparing cases without anticoagulant use with those with two or more anticoagulants (including those on warfarin and enoxaparin) used at time of surgery, a significant effect of anticoagulant use on risk of adverse effects was determined (v 2 (1) ¼ 4.122, P < 0.05) (Figure 1 ).
When patients were further split up into groups determined by type of anticoagulant used, it was determined that use of enoxaparin prior to surgery had a significant effect on risk of adverse events (P < 0.01; Fisher exact test). No other anticoagulant or combination of anticoagulants was determined to have any significant effect on surgery outcomes (Table 2) .
Certain variables such as type of SCS (percutaneous, paddle, or both), SCS location (thoracic, cervical, or both), age, gender, and diagnosis were also observed in terms of effect on risk of SCS adverse effects. Chisquare analysis determined that no effect of any of the listed variables on risk of adverse effects was significant. However, a trend was visible for SCS location, showing a larger percentage of cervical SCS patients (12%) experiencing adverse effects than thoracic SCS patients (4%; P ¼ 0.085) ( Table 3 ).
Discussion
Our results show that anticoagulant-suspended patients have no increased risk of adverse effects compared with nonanticoagulated patients. While this study is the first to systematically assess the safety of neuromodulation procedures on anticoagulant-suspended patients, reports of previous cases have similarly demonstrated the absence of adverse effects following neuromodulation surgery in similar patient populations, albeit with smaller sample sizes. One group assessing bleeding adverse effects in patients undergoing percutaneous SCS implantation showed that, of the 101 patients who received aspirin or nonsteroidal anti-inflammatory drugs within seven days of surgery, none developed hemorrhagic or neurological adverse effects [13, 14] .
The overall incidence of hemorrhagic adverse effects in neuromodulation procedures, regardless of anticoagulation status, is relatively low. The incidence of symptomatic hematoma in patients undergoing SCS implantation has been reported to be between 0.186% and 0.3% [8, 15] . In one study, 52% of patients who sustained an epidural hematoma experienced full recovery of function, while 9.6% of patients showed no recovery [8] .
As presented in Table 2 , three patients administered enoxaparin exhibited adverse effects, one developed an infection, one developed an intracranial hemorrhage, and one developed a superficial hematoma. The patient who developed a postoperative infection was 87 kg and was administered 150 mg enoxaparin qd. The indication for therapy was prior pulmonary embolism with surgery due to underlying lupus anticoagulant. The patient who developed the intracranial hemorrhage (ICH) was bridged from warfarin to 150 mg enoxaparin bid (corresponding weight of 165.6 kg) five days preoperatively and was placed on this anticoagulant regimen secondary to heart failure, previous stroke, and pacemaker. This case was a buried trial, and the ICH developed 36 hours after enoxaparin was administered. It was symptomatically managed, and the extension leads cut at the bedside as the patient was unable to return to the operating room. The ICH was cortical, affecting the somatosensory cortex, and the patient was pain free for six months. Eventually, when the pain returned, he underwent placement of an internal pulse generator.
The patient who developed a superficial hematoma had active atrial fibrillation and was bridged from warfarin to 80 mg enoxaparin bid (corresponding weight of 67.6 kg) five days preoperatively. No other cases of bleeding or hematoma were observed in the remaining patients. Of note, our two hemorrhagic adverse events occurred in patients being bridged on and off warfarin with enoxaparin. As dosing may have played a role, we now play an active role with the prescribing physician to ensure that dosing is ideal weight based and appropriate for risk. In all cases, enoxaparin was discontinued 36 hours prior to surgery and not resumed until 24 hours postoperatively.
Past studies have shown the possibility of adverse effects upon enoxaparin use. For instance, one study was terminated due to increased incidence of adverse events in the enoxaparin group in terms of postoperative intracranial hemorrhage [16] . A study in Korea showed patients experiencing bullous hemorrhagic lesions after using enoxaparin, a condition that would regress upon discontinuation of enoxaparin and recur after readministration [17] . In our study, only a small subset of patients used enoxaparin at the time of surgery; however, as previous studies have shown and as our results have determined, extra care should be taken for patients using anticoagulants in combination with enoxaparin. Our anticoagulation protocol shown in Table 4 is more conservative in some aspects compared with NACC guidelines. Specifically, we stop rivaroxaban and apixaban five days preoperatively based on our experience in neurosurgical cases. Further, we wait five days before resuming any anticoagulant if possible.
One main limitation of this study is the low rate of hematological adverse events, making it difficult to definitively generalize the safety of anticoagulant suspension in relation to nonanticoagulated patients. However, the findings of this study represent a significant step forward 
Conclusion
Perioperative management of anticoagulation therapy is critical in all surgical patients. Ultimately, the benefits gained from the improved quality of life provided by neuromodulation devices, along with the minimized risk of thromboembolic adverse effects, support the performance of neuromodulation procedures in anticoagulant-suspended patients. Here we show no increased risk of adverse effects with anticoagulants. Care should be used when bridging for epidural lead placement with enoxaparin.
